Farooq Lateef, M.D.
NPI 1982802823 · Specialist · Orlando, FL
Enrolled with Medicare as Practitioner - Dermatology · source: CMS PECOS Public Provider Enrollment (2026.04.01)
Provider details
- NPI number
- 1982802823
- Entity type
- Individual
- Primary specialty
- SpecialistOther Service Providers
- Credential
- M.D.
- Sex
- Male
- Sole proprietor
- Yes
- License
- 75932 (FL)
Specialties & taxonomies
Other Service Providers
Profile Score
A profile completeness & documented-activity index — NOT a quality, outcomes, or patient-satisfaction rating.
- Registry tenure25% of score
18 yrs in NPPES registry
- Profile completeness25% of score
100% of core fields populated
- Practice footprint15% of score
1 documented practice location
- Medicare service volume (vs. specialty peers)25% of score
3,441 Medicare services, 2024 (ranked within specialty)
- Open Payments transparency10% of score
Has Open Payments disclosures (2024)
Medicare volume is ranked against active providers in the same specialty. Signals a provider has no public data for (e.g. Medicare claims) are left out of the score entirely — never counted as zero — so providers without that data are not penalized. See the full formula and weights in our .
What this provider does (Medicare)
Based on Medicare fee-for-service claims, 2024; not all care is captured.
| Service (HCPCS) | Medicare services | Typical Medicare-allowed (2024) |
|---|---|---|
| Test for Allergy Using Skin Patch95044 | 1,680 | $5 |
| Destruction of Precancer Skin Growth, 15 Or More Growths17004 | 474 | $160 |
| Established Patient Office Or Other Outpatient Visit With Moderate Level of Decision Making, If Using Time, 30 Minutes Or More99214 | 389 | $124 |
| Destruction of Skin Growth, 15 Or More Growths17111 | 286 | $126 |
| Established Patient Office Or Other Outpatient Visit With Low Level OD Decision Making, If Using Time, 20 Minutes Or More99213 | 191 | $88 |
| Biopsy of Related Skin Growth, First Growth11102 | 135 |
What this provider prescribes (Medicare Part D)
Top drugs by Medicare Part D claim volume, 2024 · 14 distinct drugs on file.
| Drug | Part D claims (2024) | Beneficiaries |
|---|---|---|
| Betamethasone/Propylene Glycbrand: Betamethasone Diprop Augmented | 48 | 36 |
| Mupirocin | 37 | 34 |
| Fluocinonide | 28 | 20 |
| Clindamycin Phosphate | 25 | 18 |
| Mometasone Furoate | 25 | 18 |
| Acetaminophen With Codeinebrand: Acetaminophen-Codeine | 25 | 22 |
| Clobetasol Propionate | 22 | 12 |
Transparency — industry payments
Based on CMS Open Payments, 2024; not all care is captured.
$1,084 across 51 records (Open Payments 2024)
Open Payments discloses payments and transfers of value (meals, travel, consulting, research, royalties) from drug and device makers to providers. This is a transparency signal, not a verdict — such payments are legal and common, and their presence is neither an endorsement nor a criticism. Source: CMS Open Payments, program year 2024.
Practice location
Mailing address
Registry dates
- Enumerated
- 2007-07-03
- Last updated
- 2026-03-25
- Certified
- 2026-03-25
Source: CMS NPPES Data Dissemination (June 2026). NPI Central is not affiliated with CMS. Data is provided as-is from the public registry.